Autifony
develops novel pharmaceutical drug for the treatments of hearing loss... Read moreAutifony
develops novel pharmaceutical drug for the treatments of hearing loss... Read more
News
Nov 15, 2023
Pharamceutical Technology
Autifony: Autifony and Jazz enter $770.5m drug development deal
Nov 14, 2023
Sharecast
Autifony: IP Group welcomes licensing agreement between Autifony and Jazz Pharmaceuticals
Nov 14, 2023
BioSpace
Autifony: Jazz Inks $770M Deal with GSK Spinout Autifony, Nabs Two Neuro Assets
Jun 13, 2023
Life Care News
Autifony: Aclaris Therapeutics Completes Enrollment in Phase 2b Study
Mar 04, 2021
The Pharma Letter
Autifony: Boehringer renews collaboration with Autifony
Aug 26, 2020
The Pharma Letter
Autifony: Boehringer writes off 42.5 million euros in handing back Kv3 rights
May 30, 2019
BioPortfolio
Autifony: Autifony Therapeutics achieves second milestone in agreement with Boehringer Ingelheim for a novel therapeutic approach to a range of CNS disorders.
Dec 21, 2017
Pharamceutical Technology
Autifony: Boehringer partners with UK's Autifony for CNS therapeutics
Jul 10, 2017
BioPortfolio
Autifony: Autifony Therapeutics receives Orphan Drug Designation for AUT00206 for Fragile X Syndrome
May 18, 2017
BioSpace
Autifony: Autifony Therapeutics Initiates Recruitment Into Schizophrenia Clinical Trial For First-In-Class Drug
Autifony Competitors
1
2
3
4
5
6
7
8
9
10